Liberty Journal

Weight-Adjusted Hydroxychloroquine and Azithromycin Boosted Survival of Ventilated COVID-19 Patients by 200 Percent: Study

But they don’t care! Vaxx or die!

A new study has found that the use of weight-adjusted Hydroxychloroquine (HCQ) and Azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200 percent.

The observational study, which has not yet been peer-reviewed, was based on a re-analysis of 255 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic in the United States.

The researchers found that, when the HCQ/AZM combination was given at lower dosages to treat ventilated COVID-19 patients, the risk of death was over three times higher.

“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the authors of the study noted.

“By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in COVID patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better,” they wrote.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *